Compounds > cyc 202
Page last updated: 2024-09-04

cyc 202 and cx 4945

cyc 202 has been researched along with cx 4945 in 4 studies

Compound Research Comparison

Studies
(cyc 202)		Trials
(cyc 202)		Recent Studies (post-2010)
(cyc 202)		Studies
(cx 4945)		Trials
(cx 4945)		Recent Studies (post-2010) (cx 4945)
97973931662162

Protein Interaction Comparison

ProteinTaxonomycyc 202 (IC50)cx 4945 (IC50)
Death-associated protein kinase 3Homo sapiens (human)0.017
G2/mitotic-specific cyclin-B2Homo sapiens (human)0.056
Cyclin-dependent kinase 1Homo sapiens (human)0.056
Serine/threonine-protein kinase pim-1Homo sapiens (human)0.0465
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.056
Casein kinase II subunit alpha'Homo sapiens (human)0.1316
G1/S-specific cyclin-E1Homo sapiens (human)1.8
Cyclin-dependent kinase 2Homo sapiens (human)1.8
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.0417
Casein kinase I isoform alphaHomo sapiens (human)0.004
Casein kinase I isoform deltaHomo sapiens (human)0.004
Casein kinase I isoform epsilonHomo sapiens (human)0.004
Dual specificity protein kinase CLK1Homo sapiens (human)0.012
Dual specificity protein kinase CLK2Homo sapiens (human)0.0039
Dual specificity protein kinase CLK3Homo sapiens (human)0.041
Casein kinase II subunit betaHomo sapiens (human)0.2833
Casein kinase II subunit alphaHomo sapiens (human)0.1968
Casein kinase I isoform gamma-2Homo sapiens (human)0.004
Dual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)0.0069
Casein kinase II subunit alpha 3Homo sapiens (human)0.2516
G2/mitotic-specific cyclin-B3Homo sapiens (human)0.056
Homeodomain-interacting protein kinase 3Homo sapiens (human)0.045
Dual specificity protein kinase CLK4Homo sapiens (human)0.011
Casein kinase I isoform gamma-1Homo sapiens (human)0.004
Serine/threonine-protein kinase pim-2Homo sapiens (human)0.186
Serine/threonine-protein kinase TBK1Homo sapiens (human)0.035
Dual specificity tyrosine-phosphorylation-regulated kinase 1BHomo sapiens (human)0.0064

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Bazgier, V; Berka, K; Bielawska, A; Bielawski, K; Fornal, E; Gucký, T; Kryštof, V; Mojzych, M; Šubertová, V1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Jarhad, DB; Jeong, LS; Kim, HR; Mashelkar, KK; Noh, M1

Reviews

1 review(s) available for cyc 202 and cx 4945

ArticleYear
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
    Journal of medicinal chemistry, 2018, 11-21, Volume: 61, Issue:22

    Topics: Animals; Biological Products; Disease; Dyrk Kinases; Enzyme Activation; Humans; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases

2018

Other Studies

3 other study(ies) available for cyc 202 and cx 4945

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines.
    European journal of medicinal chemistry, 2014, May-06, Volume: 78

    Topics: Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; K562 Cells; MCF-7 Cells; Molecular Structure; Protein Kinase Inhibitors; Pyrazoles; Structure-Activity Relationship; Sulfonamides; Triazines; Tumor Cells, Cultured

2014
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017